Investor Relations


Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

More events are coming soon.

July 30, 2019 8:00 AM EDT
Q2 2019 Incyte Corporation Earnings Conference Call

June 17, 2019 8:00 AM EDT
Ruxolitinib Cream: Phase 2 Data in Vitiligo Webcast

June 11, 2019 2:00 PM PDT
Goldman Sachs 40th Annual Global Healthcare Conference

SEC Filings

Filing date Description Filing Group View

A statement of beneficial ownership of common stock by certain persons


An amendment to the SC 13G filing


An amendment to the SC 13G filing


Investor Contacts

Michael Booth D.Phil
Divisional VP of Investor Relations and Corporate Social Responsibility
Phone: 302.498.5914

Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141

P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536